Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T1D Exchange

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

- PMLiVE

Dexcom and Fitbit team up to tackle diabetes management

Will develop a wearable blood glucose tracking product

- PMLiVE

AZ gets US green light for new Bydureon formulation

Its latest injectable suspension proven to reduce blood sugar levels

Eli Lilly HQ

Lilly expands its immuno-oncology work with $1.8bn CureVac deal

Will work with the German firm to develop ‘next generation’ cancer vaccines

Eli Lilly HQ

Prospects for Lilly’s Verzenio hit by botched lung cancer trial

The CDK 4/6 inhibitor failed to improve overall survival in a late-stage study

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

Eli Lilly HQ

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

US drug maker to slash its workforce by 8.5%

- PMLiVE

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Analysts predict the drug could be worth $8.7bn in the next five years

- PMLiVE

Type 2 diabetes market set to soar to $64bn by 2026

Rising prevalence, progressive nature and diagnosis of the condition behind the surge

Eli Lilly HQ

Lilly wins on appeal in Alimta vitamin regimen dispute

UK Supreme Court rules in its favour over Actavis

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links